A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Cat allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Antigen Laboratories
  • Most Recent Events

    • 25 Nov 2009 According to a Planet Biopharmacueticals media release, all three treatment groups, low dose, high dose and placebo, improved symptoms significantly compared to baseline. Further phase II trials are required prior to entering phase III.
    • 16 Oct 2009 Actual patient number (167) added, actual initiation date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top